Becky Pferdehirt is an investing partner on the a16z Bio + Health team. Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation. Becky completed her postdoctoral education at Genentech, studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT.